P/E ratio for Iovance Biotherapeutics (IOVA)
P/E ratio as of May 2024 (TTM): -5.98
According to Iovance Biotherapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.97768. At the end of 2022 the company had a P/E ratio of -2.58.
P/E ratio history for Iovance Biotherapeutics from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.58 | -70.04% |
| 2021 | -8.60 | -64.97% |
| 2020 | -24.6 | 40.14% |
| 2019 | -17.5 | 153.38% |
| 2018 | -6.91 | 21.86% |
| 2017 | -5.67 | 44.5% |
| 2016 | -3.93 | -67.45% |
| 2015 | -12.1 | -24.9% |
| 2014 | -16.1 | 990.14% |
| 2013 | -1.47 | -72.22% |
| 2012 | -5.30 | 80.33% |
| 2011 | -2.94 | -95.28% |
| 2010 | -62.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -44.24% | Bahamas |
 NRC Health
NRC | 25.0 | -518.36% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.